tradingkey.logo

ImmuCell Corp

ICCC
查看詳細走勢圖
6.240USD
+0.130+2.13%
收盤 02/06, 16:00美東報價延遲15分鐘
56.45M總市值
22.75本益比TTM

ImmuCell Corp

6.240
+0.130+2.13%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+2.13%

5天

+3.65%

1月

0.00%

6月

+1.63%

今年開始到現在

+1.46%

1年

+22.11%

查看詳細走勢圖

TradingKey ImmuCell Corp股票評分

單位: USD 更新時間: 2026-02-06

操作建議

ImmuCell Corp當前公司基本面數據相對健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在藥品行業排名116/159位。機構持股佔比非常高,中期看,股價處於平穩狀態。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

ImmuCell Corp評分

相關信息

行業排名
116 / 159
全市場排名
365 / 4521
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

ImmuCell Corp亮點

亮點風險
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
業績高增長
公司營業收入穩步增長,連續3年增長42.68%
業績增長期
公司處於發展階段,最新年度總收入26.49M美元
估值高估
公司最新PE估值22.75,處於3年歷史高位
機構減倉
最新機構持股1.81M股,環比減少5.77%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉303.00K股
活躍度降低
近期活躍度降低,過去20天平均換手率-0.54

分析師目標

基於 0 分析師
--
評級
0.000
目標均價
0.00%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

ImmuCell Corp新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

ImmuCell Corp簡介

ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
公司代碼ICCC
公司ImmuCell Corp
CEOte Boekhorst (Olivier)
網址https://immucell.com/
KeyAI